Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00880581 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas

A Phase 2 study, sponsored by Ronald Levy.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target

NCT00880581: Completed Phase 2 study, sponsored by Ronald Levy.

NCT00880581 is a Phase 2 study that has completed, run by Ronald Levy. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00880581, a Phase 2 study, has completed, sponsored by Ronald Levy.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target

Study Summary

To assess the feasibility of using intra-tumoral PF-3512676 in combination with local radiation as a therapy for lowgrade b-cell lymphoma.

Primary Outcome

Overall objective response rate (OOR) at time of best response was assessed as the sum of the Complete Response (CR) rate and the Partial Response (CR, PR) rate. Response was assessed per the Cheson Criteria, as below. * Complete Response (CR) = Complete disappearance of all lesions, evidence, and effects of disease * CR/unconfirmed (CRu) = residual lymph node mass \>1.5 cm but regressed \>75%, with 1 residual lymph node mass \>1.5 cm that has regressed by \>75% and/or increased number or size

Interventions

  • DRUG PF-3512676
  • RADIATION Local radiotherapy

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2009-01
Est. Completion 2015-01
Phase Phase 2
Ronald Levy

5 total trials

What the finished NCT00880581 record still lists

NCT00880581 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 2 interventions - of which PF-3512676 is the first listed.

NCT00880581 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00880581 about?

NCT00880581 is a clinical study titled "A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas". To assess the feasibility of using intra-tumoral PF-3512676 in combination with local radiation as a therapy for lowgrade b-cell lymphoma.

What is the current status of trial NCT00880581?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2009-01. Estimated completion is 2015-01.

What interventions are being tested in trial NCT00880581?

The interventions under investigation include: PF-3512676 (DRUG), Local radiotherapy (RADIATION).

Who is sponsoring clinical trial NCT00880581?

This trial is sponsored by Ronald Levy, which has 5 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00880581's enrollment target sits among peer trials

30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00880581, the US trial registry maintained by the National Library of Medicine. NCT00880581 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.